OCGN
Ocugen, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Ocugen, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceIn November 2024, we entered into a debt financing transaction with Avenue for net proceeds of $29.2 million.
OCGN 10-Kaccession 0001628280-26-014435
SentenceCanSinoBIO is responsible for the CMC development and manufacture of clinical supplies of such product candidates and is responsible for the costs associated with such activities.
OCGN 10-Kaccession 0001628280-26-014435
SentenceUnder this agreement, CanSinoBIO is responsible for the CMC development and manufacture of clinical supplies for OCU400, OCU410 and OCU410ST.
OCGN 10-Kaccession 0001628280-26-014435
SentencePursuant to the CU Agreement, which primarily relates to OCU200, we are responsible for and control the patent prosecution of all patent families licensed under the CU Agreement.
OCGN 10-Kaccession 0001628280-26-014435
SentenceWhile we are currently collaborating with NIAID for early clinical studies for the OCU500 program, there can also be no assurance that we will be able to obtain the required funding from government agencies or strategic partners for further development of OCU500 or for development of our vaccine candidates, OCU510 and OCU520.
OCGN 10-Kaccession 0001628280-26-014435
SentenceThe Purpose Agreement was amended and restated in June 2012, pursuant to which Purpose granted Histogenics outside of Japan: (a) exclusive rights to all of Purpose's technology (owned or licensed) related to the exogenous tissue processors, which is used in the development of NeoCart, (b) continued supply of exogenous tissue processors, and (c) rights to manufacture the exogenous tissue processors at any location we choose.
OCGN 10-Kaccession 0001628280-26-014435
SentencePursuant to the SERI Agreement, which relates to NHR genes NR1D1 , NR2E3 (OCU400), RORA (OCU410 and OCU410ST), NUPR1 , and NR2C1 , from and after December 19, 2017, we have the right to assume responsibility and control patent prosecution of licensed patent families relating to these NHR genes.
OCGN 10-Kaccession 0001628280-26-014435
SentencePursuant to the SERI Agreement, which relates to NHR genes NR1D1 , NR2E3 (OCU400), RORA (OCU410 and OCU410ST), NUPR1 , and NR2C1 , from and after December 19, 2017, we have the right to assume responsibility and control patent prosecution of licensed patent families relating to these NHR genes.
OCGN 10-Kaccession 0001628280-26-014435
SentenceIn March 2014, we entered into an exclusive license agreement with CU, which was amended in January 2017 and clarified by a letter of understanding in November 2017 (as amended and clarified, the "CU Agreement").
OCGN 10-Kaccession 0001628280-26-014435
SentencePursuant to the WU Agreement, which relates to mucosal COVID-19 vaccines, Washington University maintains control of patent preparation, filing, prosecution, and maintenance, subject to our right to negotiate with WU after the first anniversary of the effective date of the WU Agreement to assume responsibility for and control of the prosecution and maintenance of the patent rights throughout the Mucosal Vaccine Territory in Washington University's name.
OCGN 10-Kaccession 0001628280-26-014435
SentenceCanSinoBIO has an exclusive license to develop, manufacture, and commercialize our modifier gene therapy platform in and for China, Hong Kong, Macau, and Taiwan (the "CanSinoBIO Territory"), and we maintain exclusive development, manufacturing, and commercialization rights with respect to our modifier gene therapy platform outside the CanSinoBIO Territory (the "Company Territory").
OCGN 10-Kaccession 0001628280-26-014435
SentenceThe Company entered into a license agreement ("Kwangdong License") with Kwangdong Pharmaceutical, Ltd ("Kwangdong") for the development and commercialization of the Company's modifier gene therapy product candidate OCU400 in September 2025.
OCGN 10-Kaccession 0001628280-26-014435
Ocugen has 10 disclosed suppliers and 2 disclosed customers in SEC filings.
Ocugen, Inc.
0.72
Expected move
No implied move.